These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 22610839)
1. [Impact of preoperative therapy with 5-α-reductase inhibitors in the treatment of benign prostatic hyperplasia]. De Stefano G; Fusco F; Arcaniolo D; Pistone A; Capece M; Sannino S; Mirone V Urologia; 2012; 79(2):149-51. PubMed ID: 22610839 [TBL] [Abstract][Full Text] [Related]
2. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis. Morlock R; Goodwin B; Gomez Rey G; Eaddy M Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026 [TBL] [Abstract][Full Text] [Related]
3. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA]. Spivak LG; Lokshin KL; Vinarov AZ Urologiia; 2015; (4):125-33. PubMed ID: 26665780 [TBL] [Abstract][Full Text] [Related]
4. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia. Kang D; Hu C; Fu Y; Wang D Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225 [TBL] [Abstract][Full Text] [Related]
5. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262 [TBL] [Abstract][Full Text] [Related]
7. Impact of medical therapy on transurethral resection of the prostate: two decades of change. Izard J; Nickel JC BJU Int; 2011 Jul; 108(1):89-93. PubMed ID: 20883490 [TBL] [Abstract][Full Text] [Related]
8. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. Campbell J; Reid J; Ordon M; Welk B Urology; 2019 Aug; 130():126-131. PubMed ID: 31129193 [TBL] [Abstract][Full Text] [Related]
9. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate. Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152 [TBL] [Abstract][Full Text] [Related]
11. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH. Sountoulides P; Gravas S Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255 [TBL] [Abstract][Full Text] [Related]
12. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746 [TBL] [Abstract][Full Text] [Related]
13. Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Strope SA; Vetter J; Elliott S; Andriole GL; Olsen MA Urology; 2015 Dec; 86(6):1115-22. PubMed ID: 26375848 [TBL] [Abstract][Full Text] [Related]
14. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998 [TBL] [Abstract][Full Text] [Related]
15. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F; Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505 [TBL] [Abstract][Full Text] [Related]
16. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]. Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A; Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093 [TBL] [Abstract][Full Text] [Related]
17. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment. Perry R; Milligan G; Anderson P; Gillon A; White M Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964 [TBL] [Abstract][Full Text] [Related]
18. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526 [TBL] [Abstract][Full Text] [Related]
19. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study. Lin VC; Liao CH; Kuo HC Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123 [TBL] [Abstract][Full Text] [Related]
20. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines]. Vinarov AZ; Spivak LG; Mironov AV Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]